Literature DB >> 8436442

Generation of cytotoxic antibodies to the B16 murine melanoma using a formalinized vaccine.

D Shrayer1, N Kouttab, A Maizel, H Wanebo, V J Hearing, D M Gersten.   

Abstract

The goal of our experiments was to determine the extent to which the humoral response to a melanoma vaccine elicits the production of cytotoxic antibodies in tumor-challenged mice. Mice were immunized with a vaccine produced from formalinized extracellular antigens (FECA) derived from B16 F10 melanomas. The production of antibodies that recognized the vaccine preparation was determined by ELISA, as was their cross-reactivity with the B700 melanoma antigen. The antibodies were shown to be anti-proliferative by inhibition of tritiated thymidine incorporation into the DNA of cultured target cells and cytotoxic by assays for complement-mediated and antibody-dependent cellular cytotoxicity. Flow cytometric analyses indicated that approximately 60% of the target cells specifically bound antibody from the immune sera. These results confirm that B700 is a significant antigenic component of the FECA vaccine, and provide encouragement for this approach to developing useful melanoma vaccines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436442     DOI: 10.1002/ijc.2910530428

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Synergistic effect of interleukin-2 and a vaccine of irradiated melanoma cells transfected to secrete staphylococcal enterotoxin A.

Authors:  David P Schrayer; Nicola Kouttab; Vincent J Hearing; Harold J Wanebo
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  Immuno-protective effect of tumor cell vaccine on Kunming mice bearing Ehrlich ascites tumor.

Authors:  Zheng Ma; Shao-Juan Zhou; Kai-Chun Wu; Bo-Rong Pan; Tai-Dong Qiao; Bao-Jun Chen; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

3.  Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine.

Authors:  D Shrayer; H Bogaars; V J Hearing; A Maizel; H Wanebo
Journal:  Cancer Immunol Immunother       Date:  1995-05       Impact factor: 6.968

4.  Immunotherapy of mice with an irradiated melanoma vaccine coupled with interleukin-12.

Authors:  D P Shrayer; B Cole; V J Hearing; S F Wolf; H J Wanebo
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 4.510

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.